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Abstract StAR, a protein synthesized in the cytoplasm and
subsequently imported into mitochondria, regulates the rate-
determining step in steroidogenesis, the transport of cholesterol
from the outer to the inner mitochondrial membrane. The active
form of StAR is the 37 kDa pre-protein, which has a short half-
life. To determine whether proteasomes participate in the
turnover of StAR, we incubated primary cultures of preovulatory
rat granulosa cells and immortalized human granulosa cells in the
presence of MG132, a specific inhibitor to proteasome catalysis.
This treatment caused accumulation of StAR in unstimulated
cells. Moreover, incubation of the cells with MG132 in the
presence of forskolin (FK), luteinizing hormone/chorionic
gonadotropin or follicular stimulating hormone augmented the
accumulation of both the 37 kDa cytoplasmic protein and the
30 kDa mature mitochondrial protein, compared to cells in-
cubated with FK or the gonadotropic hormones alone. Con-
comitantly, progesterone production was enhanced. In contrast
no elevation in the 37 kDa StAR intracellular levels or
progesterone production was observed following incubation of
the cells with the cysteine protease inhibitor E-64. The increase
of the 37 kDa StAR protein was evident after 15 min and 30 min
of incubation with MG132 (143% and 187% of control values,
respectively) with no significant elevation of the 30 kDa protein.
Accumulation of the intermediate mitochondrial 32 kDa protein
was evident after 1^2 h and the accumulation of the 30 kDa
protein was evident only after 4 h of incubation with MG132. In
contrast, no elevation in adrenodoxin, a component of the
cytochrome P450scc enzyme system, was found. These data
suggest that StAR protein is either directly or indirectly
degraded by the proteasome which may explain, in part, its
short half-life. Moreover, it seems that the cytosolic 37 kDa
protein, which is responsible for the steroidogenic activity of
StAR, is the primary proteasomal substrate and that the
inhibition of its degradation by MG132 causes the up-regulation
of progesterone production. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The steroidogenic acute regulatory protein (StAR) is syn-
thesized as a 37 kDa protein in the cytoplasm of steroidogenic
cells and is then rapidly transported into mitochondria where
it is cleaved, generating 32 kDa and 30 kDa proteins [1,2].
StAR controls the rate-limiting step in steroidogenesis, the
transport of cholesterol from the outer to the inner mitochon-
drial membrane where the cytochrome P450scc enzyme system
is located. The 37 kDa protein is believed to be the active
form of StAR and it is thought that the C-terminus of the
protein acts on the outer mitochondrial membrane to promote
cholesterol translocation [3]. The import of the cytosolic pre-
protein into the mitochondria is consequently thought to be
the event that terminates StAR’s steroidogenic activity. Be-
cause the 37 kDa pre-protein has a short half-life, it must
be produced continuously if steroidogenesis is to be main-
tained. The up-regulation of StAR by gonadotropin/cAMP
signaling has been studied in detail [2,4]. However, little is
known about its degradation. Proteasomes catalyze the deg-
radation of nuclear and cytoplasmic proteins and peptide hor-
mones including NF-UB [5], p53 [6], ornithine decarboxylase
[7] and gonadotropin releasing hormone [8]. Moreover, it was
recently documented that sperm mitochondria are degraded
by the ubiquitin^proteasome system following penetration of
the sperm to the egg during fertilization [9]. Thus, protea-
somes participate in the catabolism of proteins in a number
of subcellular compartments. In the present work we demon-
strate for the ¢rst time that inhibition of the proteolytic ac-
tivity of the proteasome results in the accumulation of StAR,
implicating the proteasome in StAR turnover.
2. Materials and methods
2.1. Reagents
MG132 was purchased from Calbiochem-Novabiochem Co. (La
Jolla, CA, USA). Forskolin (FK, a potent activator of adenylate
cyclase), E-64 (a cysteine protease inhibitor) and 4P,6-diamido-2-phen-
ylindole hydrochloride (DAPI; for DNA staining) were purchased
from Sigma Israel Chemical Ltd. (Rehovot, Israel). Antibodies to
cytochrome c were purchased from BD PharMingen (San Diego,
CA, USA). Human follicular stimulating hormone (hFSH) and hu-
man chorionic gonadotropin (hCG) were kindly provided by the NIH
and Dr. Parlow.
2.2. Cell culture
Primary granulosa cells of preovulatory follicle were obtained from
25-day-old female rats treated with 15 IU PMSG [10]. Cells were
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 1 3 8 - X
*Corresponding author. Fax: (972)-8-934 4125.
E-mail: abraham.amsterdam@weizmann.ac.il
Abbreviations: StAR, steroidogenic acute regulatory protein; FSH,
follicular stimulating hormone; hCG, human chorionic gonadotropin;
NPC1, Niemann^Pick C1; ADX, adrenodoxin
FEBS 24588 2-2-01 Cyaan Magenta Geel Zwart
FEBS 24588 FEBS Letters 490 (2001) 59^64
plated in Dulbecco’s modi¢ed Eagle’s medium (DMEM):F12 (1:1)
containing 5% fetal calf serum (FCS), on plastic tissue culture dishes.
Cells were maintained at 37‡C in 5% CO2 in humidi¢ed incubators.
2.3. Establishment of human granulosa cell lines
The human granulosa cell line HO-23 was established by triple
transfection of primary human granulosa cells obtained from an in
vitro fertilization program, with SV40 DNA, Ha-ras oncogene, and a
temperature sensitive mutant of p53 (p53Val135) as described [11].
The rat FSH responsive cell line (rFSHR-17) was established by triple
transfection of preovulatory granulosa cells with SV40 DNA, Ha-ras
oncogene, and FSH receptor plasmid [12]. Cells were maintained in
DMEM/F12 (1:1) containing 5% FCS, at 37‡C in the presence of 5%
CO2 in a humidi¢ed incubator.
2.4. Biochemical assays
Progesterone measurement. Progesterone accumulated in the cul-
ture medium was determined by radioimmunoassay [13,14]. Antibod-
ies to progesterone were kindly provided by Dr. F. Kohen (The Weiz-
mann Institute of Science, Rehovot, Israel).
Protein assay. Protein was quanti¢ed by the Bradford method [15].
2.5. Western blot analysis
Western blot analysis was carried out as described [11]. Samples
containing equal amounts of protein (30 Wg) were separated by 12%
(to detect StAR and Niemann^Pick C1 protein (NPC1) [16]) or 15%
(to detect adrenodoxin (ADX)) acrylamide SDS^PAGE. Anti-human
ADX polyclonal antibodies were kindly provided by Dr. W.L. Miller
(University of California, San Francisco, CA, USA). Anti-NPC1 N-
terminus polyclonal antiserum was used to detect NPC1 [17].
2.6. Microscopy
Phase contrast and immuno£uorescent microscopy was performed
using a Zeiss Axioskop Microscope (Carl Zeiss, Oberkochen, Ger-
many).
Fig. 1. Content of NPC1, StAR and ADX in immortalized human (HO-23: A,B) and rat (rFSHR-17: C) granulosa cells incubated at 37‡C in
the absence or presence of FK or FSH respectively for 15 h. The proteasome inhibitor MG132 or the cysteine protease inhibitor E-64 were
added to the indicated cultures during the last 5 h of incubation. Cell lysates were separated by acrylamide gel electrophoresis, transferred to
nitrocellulose membrane and reacted with the appropriate antibodies. M, enriched fraction of rat granulosa cell mitochondria.
C
Fig. 2. A: StAR content by Western blot in preovulatory granulosa
cells incubated at 37‡C for 7 h in the absence or presence of hCG
(3 IU/ml), and in the absence or presence of MG132 (10 WM). Den-
sitometric tracing of the 37 kDa and 30 kDa StAR in the di¡erent
treatments is shown above or below the blot, respectively. B: Pro-
gesterone secretion from preovulatory granulosa cells incubated at
37‡C for 7 h in the absence or presence of hCG (3 IU/ml). Data
are the mean þ S.D. (n = 3). a is di¡erent from c (P6 0.05). aP is dif-
ferent from cP (P6 0.01), and aQ is di¡erent from cQ (P6 0.005). a,
c are di¡erent from b, d, respectively (P6 0.001). aP, cP are di¡erent
from bP, dP, respectively (P6 0.05). aQ, cQ are di¡erent from bQ, dQ,
respectively (P6 0.001).
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2.7. Statistical analysis
Analysis of progesterone production and densitometer tracing on
Western blot autoradiograms (mean þ S.D.) were performed using un-
paired Student’s t test and di¡erences were signi¢cant if P values were
6 0.05.
3. Results
In order to examine whether a speci¢c proteasome inhibitor
MG132 [18] can a¡ect the intracellular level of StAR, immor-
talized human granulosa cells and preovulatory rat granulosa
cells were incubated for 5^7 h with 10^30 WM of MG132 in
the presence or absence of 25 WM of FK. There was a pro-
nounced elevation in the 30 kDa and 37 kDa StAR proteins
in immortalized human granulosa cells treated with MG132 in
the absence of FK, but the augmentation was much more
dramatic when cells were stimulated with FK (Fig. 1A). In
contrast no elevation in 30 kDa and 37 kDa StAR protein
was observed either in the presence or absence of FK upon
incubation of the cells with 10 WM of an inhibitor of lysoso-
mal proteases E-64 [19^21] (Fig. 1B). No elevation in 37 kDa
StAR protein was evident even at 30 WM or 100 WM of E-64
(data not shown). An elevation in 30 kDa protein and a dra-
matic increase in 37 kDa protein was also evident in rFSHR-
Fig. 3. Expression of StAR by immunocytochemistry in primary preovulatory granulosa cells treated with hCG in the absence or presence of a
proteasome inhibitor MG132. Cells were incubated with 5% serum in the absence (a^c) or the presence (d) of 10 WM MG132 or with 3 IU/ml
hCG in the absence (e) or presence (f) of MG132 for 5 h at 37‡C. Cells were doubly stained (a, b) with DAPI (blue) (a) and anti-cytochrome
c (green) (b) to visualize and to verify the location and the intactness of the mitochondria (dotted green £uorescence; wide arrows), lipid drop-
lets, characteristic for steroidogenic cells (arrow) and the nucleus (N). Cells were stained with anti-StAR antibodies (c^f). Note localization of
StAR in mitochondria (dotted green £uorescence) and some di¡use staining in cytoplasm in MG132-treated cells (d, f). a: Combined phase
and £uorescent microscopy; b^f: £uorescent microscopy.
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17 cells treated with FSH and MG132 compared to FSH
treatment alone (Fig. 1C). Moreover a similar phenomenon
was observed in primary cultures of preovulatory rat granu-
losa cells in the basal state or when stimulated with hCG. The
increase in 37 kDa protein was much more pronounced than
increase in 30 kDa protein (Fig. 2A). MG132 treatment did
not elevate levels of two other proteins that are involved in
cholesterol metabolism; the 14 kDa ADX protein, a compo-
nent of the mitochondrial cholesterol side-chain cleavage sys-
tem, and the 146 kDa NPC1 protein, a late endosome com-
ponent that plays a central role in the tra⁄cking of free
cholesterol out of lysosomes (Fig. 1A). On the contrary
some decrease of NPC1 levels was observed in the presence
of FK and MG132.
In order to examine whether elevation of StAR content by
MG132 enhances steroidogenesis we measured progesterone
production in response to the various treatments. A signi¢cant
elevation in progesterone formation was evident in MG132-
treated cells (Fig. 2B). In order to determine whether the
StAR protein is localized in the mitochondria in MG132-
treated cells we immunostained cells with StAR antibody. In-
deed, StAR was found to be localized in mitochondria of the
Fig. 4. Expression of StAR in preovulatory rat granulosa cells in the presence of a proteasome inhibitor MG132. Cells were isolated from
PMSG-treated 25-day-old female rats and cultured for 24 h in 5% FCS in the absence or presence of 3 IU/ml hCG, and subsequently with
20 WM MG132 for 15 min, 30 min, or 120 min. Cell lysates were electrophoresed, blotted and incubated with rabbit antiserum to StAR pro-
tein. At the top and bottom, densitometric tracing of the 37 kDa and 30 kDa protein, respectively.
FEBS 24588 2-2-01 Cyaan Magenta Geel Zwart
K. Tajima et al./FEBS Letters 490 (2001) 59^6462
cells. Interestingly some elevation of cytoplasmic StAR was
evident in cells treated with MG132 without or with hCG,
which presumably re£ects accumulation of the 37 kDa protein
(Fig. 3).
In order to examine the rate of accumulation of StAR sub-
sequent to MG132 treatment we preincubated preovulatory
rat granulosa cells for 12 h in the presence or absence of
hCG (3 IU/ml) followed by incubation with and without
MG132 for 15 min until 8 h. Before the addition of MG132
there was elevated content of 37 kDa protein in hCG-treated
cells, and there was additional 43% increase in 37 kDa protein
in hCG+MG132-treated cells at 15 min compared to cells
treated with hCG alone (Fig. 4). Further increases of 37
kDa protein in MG132-treated cells preincubated with hCG
(187%) were evident 30 min following MG132 treatment. In-
creasing levels of 32 kDa protein were evident in MG132-
treated cells for 1^2 h either preincubated or not with hCG,
while modest increases in 30 kDa protein were evident only
following 7 h of incubation with MG132 (Fig. 2).
4. Discussion
StAR protein plays a key role in rapid modulation of ster-
oidogenesis in the ovary [22], testis [23] and the adrenal [24]. It
has previously been demonstrated that expression of StAR is
increased via a gonadotropin^cAMP^protein kinase A cas-
cade involving steroidogenic factor 1 [25,26]. Interestingly,
StAR expression is also independently elevated by growth
factors such as basic ¢broblastic growth factor [27] without
the elevation of intracellular cAMP levels. In the immortalized
granulosa cell line established in our laboratory [11,12] pro-
gesterone production declines within several hours after re-
moval of the stimulant (FSH or FK, Sasson and Amsterdam,
unpublished). This is consistent with a rapid loss of StAR
functional activity.
In the present work we demonstrate that the 37 kDa pre-
cursor and to a lesser extent the 30 kDa mature protein ac-
cumulate upon inhibition of the proteasome, a multicatalytic
protease [28] that degrades intracellular proteins that must be
turned over rapidly. The preferential elevation of StAR with-
out increases in NPC1 and the cytochrome P450scc enzyme
system component, ADX, was associated with increased pro-
gesterone production, consistent with the notion that StAR
regulation is the limiting step in steroidogenesis. Our studies
demonstrate that the 37 kDa StAR protein is elevated within
15 min of exposure of both primary and immortalized gran-
ulosa cells to MG132. These observations are consistent with
pulse-chase experiments where a clear degradation of the pro-
tein was also evident within a similar time frame [3]. Subse-
quent accumulation of 32 kDa protein can be explained by
the accumulation of 37 kDa protein which is subsequently
imported into mitochondria and processed to the 32 kDa
and mature 30 kDa forms.
Only modest accumulation of the 30 kDa protein was ob-
served in primary preovulatory granulosa cells, which have
abundant 30 kDa StAR protein in the basal state. In contrast,
in the immortalized HO-23 human granulosa cells which con-
tain extremely low levels of StAR in non-stimulated state,
accumulation of 30 kDa protein was evident within 5 h of
incubation with MG132 and both 30 kDa and 37 kDa pro-
teins were elevated when cells were pre-stimulated with FK
for 10 h. The inability of MG132 to elevate intracellular levels
of ADX or NPC1, proteins involved in cholesterol side-chain
cleavage and intracellular cholesterol tra⁄cking, respectively,
which do not have short half-lives, contrasts with the e¡ects
of MG132 on StAR. This is concordant with the unique re-
quirements for acute modulation of the rate-limiting step in
steroidogenesis. Moreover our data strengthen the notion that
the 37 kDa protein is the form of StAR that promotes trans-
location of cholesterol into the mitochondria because of the
tight relationship between its accumulation and enhanced ster-
oidogenesis that was demonstrated in this work.
Because of the relative low amount of 37 kDa StAR and
the poor antibodies to ubiquitin, we were not able in prelimi-
nary experiments to demonstrate that the 37 kDa StAR is
ubiquitinated prior to its degradation [29]. However, the
inability of the calpain inhibitor E-64 to elevate the intra-
cellular levels of StAR would strengthen our argumenta-
tion of the responsibility of the proteasome system for the
degradation of StAR. Experiments designed to over-express
StAR and labeled ubiquitin may clarify this issue in the fu-
ture. Thus, at the present time we cannot rule out the pos-
sibility that StAR can be degraded by proteasomes with-
out ubiquitination, which may be characteristic for proteins
which are very rapidly degraded like ornithine decarboxylase
[30].
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